“While SIWA’s focus remains on developing a powerful therapeutic for aggressive cancers, the Covid-19 pandemic presented us with an opportunity to explore how 318H could also be used to treat infectious diseases.”
In this interview, our CEO and Chief Scientific Officer, Lewis Gruber, discusses the results of our recent preclinical tests, which confirmed 318H shows promise to become both a comprehensive cancer therapy and a broad-spectrum antiviral drug.
Read the full interview here: https://startup.info/lewis-gruber-siwa-therapeutics/